Literature DB >> 10202134

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

J S Ross1, J A Fletcher.   

Abstract

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely studied in breast cancer. The potential value of HER-2/neu status for the prediction of disease outcome and response to therapy in breast cancer is presented in the light of a series of recently published studies showing a range of impact on the outcome of patients treated with hormonal, cytotoxic and radiation therapies. This review includes the application of serum-based HER-2/neu testing and the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment. Copyright 1999 Academic Press.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10202134     DOI： 10.1006/scbi.1998.0083

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  31 in total

Review 1.  Monoclonal antibodies.

Authors:  P N Nelson; G M Reynolds; E E Waldron; E Ward; K Giannopoulos; P G Murray
Journal:  Mol Pathol       Date:  2000-06

Review 2.  Optical imaging-guided cancer therapy with fluorescent nanoparticles.

Authors:  Shan Jiang; Muthu Kumara Gnanasammandhan; Yong Zhang
Journal:  J R Soc Interface       Date:  2009-09-16       Impact factor: 4.118

Review 3.  Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network.

Authors:  K L Troyer; D C Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

4.  Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer.

Authors:  J J Frietsch; T G P Grunewald; S Jasper; U Kammerer; S Herterich; M Kapp; A Honig; E Butt
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

Review 5.  The curability of breast cancer and the treatment of advanced disease.

Authors:  Valentina Guarneri; Pier Franco Conte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-24       Impact factor: 9.236

6.  Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer.

Authors:  Päivikki Kauraniemi; Tuula Kuukasjärvi; Guido Sauter; Anne Kallioniemi
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

7.  Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.

Authors:  Priti Lal; Paulo A Salazar; Marc Ladanyi; Beiyun Chen
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

8.  Examination of tumour histopathology and gene expression in a neu/S100A4 transgenic model of metastatic breast cancer.

Authors:  Peter T Simpson; Balvinder S Shoker; Roger Barraclough; Nigel Halliwell; Philip S Rudland; D Ross Sibson; Michael P A Davies
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

9.  Gene copy numbers of HER family in breast cancer.

Authors:  Anna Zaczek; Marzena Wełnicka-Jaśkiewicz; Krzysztof Piotr Bielawski; Janusz Jaśkiewicz; Andrzej Badzio; Włodzimierz Olszewski; Piotr Rhone; Jacek Jassem
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-28       Impact factor: 4.553

10.  Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer.

Authors:  Weiguo Sui; Minglin Ou; Jiejing Chen; Youhua Wan; Hongbo Peng; Minfang Qi; He Huang; Yong Dai
Journal:  World J Surg Oncol       Date:  2009-11-09       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.